Literature DB >> 11559705

Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage.

T Ando1, T Kawabe, H Ohara, B Ducommun, M Itoh, T Okamoto.   

Abstract

Although a major effect of p21, a cyclin-dependent kinase inhibitor, is considered to be exerted during G(1) phase of the cell cycle, p21 gene knock-out studies suggested its involvement in G(2)/M checkpoint as well. Here we demonstrate evidence that p21 is required for the cell cycle arrest at G(2) upon DNA damage. We found that expression of wild-type p21 (p21(WT)), not mutant p21 (p21(PCNA-)) lacking the interaction with proliferating cell nuclear antigen (PCNA), caused G(2) cell cycle arrest in p53-deficient DLD1 colon cancer cell line after the DNA damage by treatment with cis-diamminedichloroplatinum (II). We also found that p21(WT) was associated with Cdc2/cyclin B1 together with PCNA. Furthermore, coimmunoprecipitation experiments revealed that PCNA interacted with Cdc25C at the G(2)/M transition, and this interaction was abolished when p21(WT) was expressed presumably due to the competition between p21(WT) and Cdc25C in the binding to PCNA. These findings suggest that p21 plays a regulatory role in the maintenance of cell cycle arrest at G(2) by blocking the interaction of Cdc25C with PCNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559705     DOI: 10.1074/jbc.M106460200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence.

Authors:  Salvador Macip; Makoto Igarashi; Li Fang; Angus Chen; Zhen-Qiang Pan; Sam W Lee; Stuart A Aaronson
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

2.  Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.

Authors:  George Kontopidis; Su-Ying Wu; Daniella I Zheleva; Paul Taylor; Campbell McInnes; David P Lane; Peter M Fischer; Malcolm D Walkinshaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-28       Impact factor: 11.205

Review 3.  Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

Authors:  Alexander H Stegh
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

Review 4.  The enigmatic effects of caffeine in cell cycle and cancer.

Authors:  Ann M Bode; Zigang Dong
Journal:  Cancer Lett       Date:  2006-05-18       Impact factor: 8.679

5.  Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases.

Authors:  Oras Mistafa; Aram Ghalali; Sandeep Kadekar; Johan Högberg; Ulla Stenius
Journal:  J Biol Chem       Date:  2010-07-06       Impact factor: 5.157

6.  Bryostatin-1 causes radiosensitization of BMG-1 malignant glioma cells through differential activation of protein kinase-Cδ not evident in the non-malignant AA8 fibroblasts.

Authors:  Raghubendra Singh Dagur; Shashank Hambarde; Sudhir Chandna
Journal:  Mol Cell Biochem       Date:  2014-12-04       Impact factor: 3.396

7.  p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.

Authors:  Yong Ding; Yucai Wang; Jun Chen; Yunsheng Hu; Zhuo Cao; Pengcheng Ren; Yong Zhang
Journal:  Tumour Biol       Date:  2013-12-11

8.  C/EBPα regulates CRL4(Cdt2)-mediated degradation of p21 in response to UVB-induced DNA damage to control the G1/S checkpoint.

Authors:  Jonathan R Hall; Michael S Bereman; Angelito I Nepomuceno; Elizabeth A Thompson; David C Muddiman; Robert C Smart
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Ent-11α-Hydroxy-15-oxo-kaur-16-en-19-oic-acid Inhibits Growth of Human Lung Cancer A549 Cells by Arresting Cell Cycle and Triggering Apoptosis.

Authors:  Li Li; George G Chen; Ying-Nian Lu; Yi Liu; Ke-Feng Wu; Xian-Ling Gong; Zhan-Ping Gou; Ming-Yue Li; Nian-Ci Liang
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

10.  Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance.

Authors:  Robert G Lingeman; Robert J Hickey; Linda H Malkas
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-05       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.